Back to Top


Tepotinib granted FDA priority review for METex14 NSCLC

FDA BTD and NDA filing based on data from ongoing phase 2 VISION study; no PDUFA date mentioned (EMD press release)

Phase III CROWN meets primary endpoint PFS in ALKpos, advanced NSCLC

The confirmatory CROWN study compared lorlatinib to crizotinib in tx-naïve, ALKpos NSCLC. The study met its’ primary endpoint (PFS by BIRC) at interim analysis. Data has not been presented (Pfizer press release).


Subscribe to RSS - NSCLC